Use este identificador para citar ou linkar para este item: http://repositorio.ufc.br/handle/riufc/40252
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorBarbosa, Sabrina Carneiro Melo-
dc.contributor.authorPereira, Venúcia B.M.-
dc.contributor.authorWong, Deysi Viviana Tenazoa-
dc.contributor.authorSantana, Ana P.M.-
dc.contributor.authorLucetti, Larisse T.-
dc.contributor.authorCarvalho, Lucas L.-
dc.contributor.authorBarbosa, Carlos Rodrigues Nogueira-
dc.contributor.authorCallado, Rodrigo B.-
dc.contributor.authorSilva, Carolina Azevedo Alcantara-
dc.contributor.authorLopes, C. Diego H.-
dc.contributor.authorBrito, Gerly A.C.-
dc.contributor.authorAlencar, Nylane Maria Nunes de-
dc.contributor.authorLima-Júnior, Roberto C.P.-
dc.date.accessioned2019-03-12T11:20:02Z-
dc.date.available2019-03-12T11:20:02Z-
dc.date.issued2019-
dc.identifier.citationBARBOSA, S. C. M. et al. Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation. Brazilian Journal of Medical and Biological Research, Ribeirao Preto, v. 52, n. 3, e8251, 2019.pt_BR
dc.identifier.issn1414-431X-
dc.identifier.urihttp://www.repositorio.ufc.br/handle/riufc/40252-
dc.description.abstractOral mucositis (OM) is a common and dose-limiting side effect of cancer treatment, including 5-fluorouracil (5-FU) andradiotherapy. The efficacy of the therapeutic measures to prevent OM is limited and disease prevention is not fully observable.Amifostine is a cytoprotective agent with a described anti-inflammatory potential. It is clinically used to reduce radiotherapy andchemotherapy-associated xerostomia. This study investigated the protective effect of amifostine on an experimental model ofOM. Hamsters were divided into six groups: saline control group (5 mL/kg), mechanical trauma (scratches) of the rightcheek pouch; 5-FU (60 and 40 mg/kg,ip, respectively, administered on days 1 and 2); amifostine (12.5, 25, or 50 mg/kg)+5-FU+scratches. Salivation rate was assessed and the animals were euthanized on day 10 for the analysis of macroscopicand microscopic injury by scores. Tissue samples were harvested for the measurement of neutrophil infiltration and detection ofinflammatory markers by ELISA and immunohistochemistry. 5-FU induced pronounced hyposalivation, which was prevented byamifostine (Po0.05). In addition, 5-FU injection caused pronounced tissue injury accompanied by increased neutrophilaccumulation, tumor necrosis factor-alpha (TNF-a), and interleukin-1 beta (IL-1b) tissue levels, and positive immunostaining forTNF-a, IL-1b, and inducible nitric oxide synthase (iNOS). Interestingly, amifostine prevented the inflammatory reaction andconsequently improved macroscopic and microscopic damage (Po0.05vs5-FU group). Amifostine reduced inflammation andprotected against 5-FU-associated oral mucositis and hyposalivation.pt_BR
dc.language.isoenpt_BR
dc.subjectMucositept_BR
dc.subjectMucositispt_BR
dc.subjectAmifostinapt_BR
dc.subjectAmifostinept_BR
dc.subjectCitocinaspt_BR
dc.subjectCytokinespt_BR
dc.titleAmifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivationpt_BR
dc.typeArtigo de Periódicopt_BR
Aparece nas coleções:PPGF - Artigos publicados em revistas científica

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
2019_art_scmbarbosa.pdf4,17 MBAdobe PDFVisualizar/Abrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.